| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
6,166 |
4,916 |
$409K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
3,677 |
3,293 |
$245K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
2,727 |
2,314 |
$108K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
959 |
885 |
$94K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
733 |
655 |
$67K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
640 |
576 |
$65K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
505 |
475 |
$51K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
3,448 |
2,772 |
$49K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
238 |
231 |
$27K |
| 99173 |
|
1,778 |
1,622 |
$12K |
| 96127 |
|
449 |
415 |
$7K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
462 |
422 |
$5K |
| 36416 |
|
1,293 |
1,199 |
$4K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
55 |
50 |
$4K |
| 92567 |
|
324 |
269 |
$3K |
| 87081 |
|
387 |
351 |
$2K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
53 |
49 |
$1K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
105 |
97 |
$1K |
| 94760 |
|
250 |
211 |
$356.90 |
| 90651 |
|
26 |
26 |
$227.18 |
| 90686 |
|
1,409 |
1,292 |
$155.08 |
| 85018 |
|
1,293 |
1,200 |
$24.86 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
22 |
22 |
$20.89 |
| 90685 |
|
60 |
56 |
$0.10 |
| 90715 |
|
14 |
14 |
$0.01 |
| 90671 |
|
128 |
124 |
$0.00 |
| 90633 |
|
58 |
56 |
$0.00 |
| 90672 |
|
91 |
90 |
$0.00 |
| 90670 |
|
315 |
279 |
$0.00 |
| D0145 |
Oral evaluation for a patient under three years of age |
58 |
58 |
$0.00 |
| 90710 |
|
31 |
31 |
$0.00 |
| 81002 |
|
14 |
14 |
$0.00 |
| 90680 |
|
27 |
27 |
$0.00 |
| 90697 |
|
27 |
27 |
$0.00 |
| 90647 |
|
110 |
94 |
$0.00 |
| G0136 |
Administration of a standardized, evidence-based assessment of physical activity and nutrition, 5-15 minutes, not more often than every 6 months |
177 |
171 |
$0.00 |
| 90619 |
|
16 |
16 |
$0.00 |
| 90696 |
|
12 |
12 |
$0.00 |
| D0150 |
Comprehensive oral evaluation - new or established patient |
12 |
12 |
$0.00 |
| 90723 |
|
12 |
12 |
$0.00 |